eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank

1/2018
vol. 10
 
Share:
Share:
abstract:
Original paper

Accelerated partial breast irradiation in a single 18 Gy fraction with high-dose-rate brachytherapy: preliminary results

Javier Anchuelo Latorre
,
Piedad Galdós
,
Lucía Alonso Buznego
,
Ana García Blanco
,
Juan Cardenal
,
María Ferri
,
Iván Díaz de Cerio
,
Elisabet Arrojo
,
Nicolás Sierrasesúmaga
,
Mónica González Noriega
,
Ana De Juan Ferré
,
Rosa Fabregat
,
Samuel Ruíz
,
Pedro J. Prada

J Contemp Brachytherapy 2018; 10, 1: 58–63
Online publish date: 2018/02/28
View full text Get citation
 
Introduction
To evaluate the feasibility of acute and chronic toxicity in patients suitable for accelerated partial breast irradiation (APBI) in a single 18 Gy fraction with multicatheter high-dose-rate (HDR) brachytherapy, as well as cosmetic and oncological outcomes.

Material and methods
Between September 2014 and March 2016, twenty consecutive patients with low-risk invasive and ductal carcinoma in situ were treated with interstitial multicatheter HDR brachytherapy in a single 18 Gy fraction.

Results
Median age was 63.5 years (range, 51-79). Acute toxicity was observed in seven patients, while the pain during following days and hematoma were seen in four patients. With a median follow-up of 24 months, late toxicity was found in one patient with fat necrosis g2 and fibrosis g2 in another patient. The overall survival (OS) and locoregional control (LC) was 100%. Disease-free survival (DFS) and distant control was 95%. Good to excellent cosmetic outcomes were noted in 80% of patients and fair in 4 patients (20%).

Conclusions
This is the first report in the medical literature that focuses on feasibility and acute and chronic toxicity, with a median follow-up of 24 months (range, 20-40). The protocol is viable and convenient. However, a longer follow-up is needed to know chronic toxicity and oncologic outcomes.

keywords:

APBI, brachytherapy, breast cancer, morbidity

 
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.